ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...

ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...

In a recent Sermo survey of 100 U.S. urologists, 57 percent indicated they were unable to treat patients in the last 12 months due to a lack of access to TICE® BCG. The alternative BCG source has ...

The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

The TICE BCG market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX ...

ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...

Providers who are unable to source TICE BCG will now be able to access rBCG through the expanded access program. Developed by the Serum Institute of India, the rBCG product, which has been ...

ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an “alternative source of BCG.” Specifically, the company will now be able to provide this ...

Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...

to supply a new Bacillus Calmette-Guérin (BCG) source for bladder cancer treatment in the U.S. This development comes as a response to the shortage of TICE® BCG, which has affected patient ...